ArticleCurrent ophthalmology reports2021
Update on the Management of Ocular Surface Squamous Neoplasia.
Article in Current ophthalmology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Ruthenium-106 ocular surface brachytherapy for incompletely excised conjunctival melanoma and squamous cell carcinoma.Journal of contemporary brachytherapy · 2026Article
- Artificial Intelligence in Ocular Surface Tumors: Current Advances, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2026Review
- Immune Checkpoint Inhibitors in the Treatment of Ocular Surface Cancers: A Review.Seminars in ophthalmology · 2025Review
- A case of rapidly growing conjunctival squamous cell carcinoma in a 3-year-old child with xeroderma pigmentosum: a case report.Journal of medical case reports · 2025Article
- EZH2 expression in corneal and conjunctival intraepithelial neoplasia and squamous cell carcinoma: a potential marker for diagnosis.International ophthalmology · 2025Article
- Spontaneously resolved invasive conjunctival squamous cell carcinoma with anterior chamber invasion in low-grade lymphoma patient.American journal of ophthalmology case reports · 2025Article
- Update in the Diagnosis and Management of Ocular Surface Squamous Neoplasia (OSSN).Journal of clinical medicine · 2025Review
- Oncological principles in the management of ocular surface squamous neoplasia - A Review.Indian journal of ophthalmology · 2025Review
- Infectious etiologies of conjunctival tumors.Expert review of ophthalmology · 2025Article
- IFNα2b/5-FU inhibits proliferation and cell cycle of squamous carcinoma cell line Cal27.International journal of ophthalmology · 2025Article
- Chronic inflammation as a proposed risk factor for ocular surface squamous neoplasia.The ocular surface · 2024Article
- Toluidine blue 1% eye drop versus optical coherence tomography for margin delimitation of ocular surface squamous neoplasia.European journal of ophthalmology · 2024Article
- Asymptomatic chronic red eye: A surgical technique case report.International journal of surgery case reports · 2023Article
- Medical treatment for ocular surface squamous neoplasia.Eye (London, England) · 2023Review
- Mesoporous Silica Nanoparticles Coated with Carboxymethyl Chitosan for 5-Fluorouracil Ocular Delivery: Characterization, In Vitro and In Vivo Studies.Molecules (Basel, Switzerland) · 2023Article
- Yes-associated protein-1 overexpression in ocular surface squamous neoplasia; a potential diagnostic marker and therapeutic target.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewTo review and update the latest findings in diagnosis and management of ocular surface squamous neoplasia (OSSN). RECENT
findingsOSSN is the most common anterior segment neoplastic disease process. Several ocular surface imaging techniques have been developed for the early diagnosis and management of clinical and subclinical ocular surface squamous neoplasia, including high-resolution optical coherence tomography (HR-OCT), in vivo confocal microscopy, and ultrasound biomicroscopy. Treatment modalities include both surgical and medical management, with a recent trend towards primary and adjunctive pharmacotherapy. SUMMARY: There is increasing use of HR-OCT for the diagnosis and monitoring of clinical and subclinical OSSN lesions. Topical pharmacotherapy agents, including interferon α-2b, 5-fluorouracil, and mitomycin C, have demonstrable efficacy in the treatment of OSSN and their use may be dictated based upon tumor factors, patient factors, cost, and side effect profile. Both surgical excision and adjunctive topical medications have excellent success, with the favored treatment method trending towards topical pharmacotherapy as primary therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.